Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
00:12:52 - Health Sharing vs
Hope, Hype, and a Healthy Dose of Caution Dr Andrew Greenland 11mo GLP-1 Agonists in Type 1 Diabetes: When and Why to Use Them Gerti Tashko, MD 1y Designing Opioid Treatment Services for Those Most Likely to Die Mark Gilman 5mo From Innovation to Integration: Positioning Human, Analog and Basal Insulin in Indias Post Semaglutide Landscape What Marketers Should Know Vishwanath Prasad 4mo Ozempic And Other Weight Loss Drugs Will Only Work With Digital Health Bertalan Mesk, MD, PhD 2y Virta Health and the Business of Getting Patients Off the Forever Drug Graham Muhanga 3w Are there really not enough studies on GLP-1s
10.1074/jbc.RA118.007122 64 DuanY.LiF.LiY.TangY.KongX.FengZ.et al
In Phase 2 trials, the 8mg dose produced 22.8% average weight loss while 12mg produced 24.2%, a difference of about 1.4%